Pattern and prognostic factors in patients with malignant ascites: A retrospective study

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 945-949

  Ayantunde, A A ^a   Parsons, S L ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cancers; Chemotherapy; Malignant ascites; Paracentesis; Prognotic factors; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DIURETIC AGENT; FUROSEMIDE; PLASMA PROTEIN; SERUM ALBUMIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; ASCITES; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PARACENTESIS; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 34447298354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl499     Document Type: Article

References (17)

1. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-342.
2. Parsons SL, Watson SA, Steele RJC. Malignant ascites [Review], Br J Surg 1996; 83: 6-4.
3. Runyon BA, Hoefs JC, Morgan IR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104-1109.
4. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites: clinical and experimental observations. Ann Surg 1986; 203: 644-651.
5. Parsons SL, Lang MW, Steele RJC. Malignant ascites: A 2 year review from a teaching hospital. Eur J Surg Oncol 1996; 22: 237-239.
6. Mackey JR, Venner PM. Malignant ascites: Demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996; 6: 474-480.
7. Wilailak S, Linasmita V, Srivannaboon S, Malignant ascites in female patients: A seven-year review. J Med Assoc Thai 1999; 82: 15-19.
8. Appelqvist P, Silvo J, Salmela L, Kostiainen S. On the treatment and prognosis of malignant ascites: Is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 1982; 20: 238-242.
9. Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer 1989; 64: 753-755.
10. Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg 1982; 69: 441-442.
11. Pockros PJ, Esrason KT, Nguyen C et al. Mobilization of malignant ascites with oiuretics is dependent on ascitic fluid characteristics. Gastroeneterology 1992; 103: 1302-1306.
12. Easson A, Bezjak A, Ross A et al. Changes in symptoms after paracentesis for symptomatic malignant ascites. J Clip Oncol 2005; 16: 6071 (Suppl).
13. Lee CW, Bociek G, Fraught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998; 16: 96-101.
14. Marme A, Straub G, Bastert G et al. Intraperitoneal bispecific antibody (HAE125XOKT3) therapy inhibits malignant ascites proauction in advanced ovarian carcinoma. Int J Cancer 2002; 101: 183-189.
15. Reiss MM, Strohlein MA, Jaeger M et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117: 435-443.
16. Jaeger M, Stroehlein MA, Schoberth A et al. Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumour cells from malignant ascites in ovarian cancer: Results of a phase I/II study. J Clin Oncol 2004; 22 (4S): 2504.
17. Byrne AT, Ross L, Holash J et al. Vascular endothelial growth factor-Trap decreases tumour burden, inhibits ascites and causes dramatic vascular remodelling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721-5728.